APA (7th ed.) Citation

C, X., Y, Z., PA, R., VM, H., W, G., G, K., . . . Y, L. (2017). Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(19), 5869. https://doi.org/10.1158/1078-0432.CCR-17-0483

Chicago Style (17th ed.) Citation

C, Xu, et al. "Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 23, no. 19 (2017): 5869. https://doi.org/10.1158/1078-0432.CCR-17-0483.

MLA (9th ed.) Citation

C, Xu, et al. "Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 23, no. 19, 2017, p. 5869, https://doi.org/10.1158/1078-0432.CCR-17-0483.